⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VRCA News
Verrica Pharmaceuticals Inc. Common Stock
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
globenewswire.com
VRCA
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
globenewswire.com
VRCA
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
globenewswire.com
VRCA
Form 8-K
sec.gov
VRCA
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
globenewswire.com
VRCA
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
globenewswire.com
VRCA
Form 8-K
sec.gov
VRCA
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results
globenewswire.com
VRCA
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
globenewswire.com
VRCA
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
globenewswire.com
VRCA